Heightened expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-δ human endometrial adenocarcinoma

B. J. Tong, J. Tan, L. Tajeda, S. K. Das, J. A. Chapman, R. N. DuBois, S. K. Dey

Research output: Contribution to journalArticle

112 Citations (Scopus)

Abstract

Epidemiological studies indicate that nonsteroidal anti-inflammatory drugs (NSAIDs) significantly reduce the risk and mortality from colorectal cancer, in part by inhibiting prostaglandin (PG) synthesis. Cyclooxygenase (COX), the rate-limiting enzyme in PG biosynthesis, exists in two isoforms, COX-1 and COX-2. Genetic and pharmacological evidences suggest that COX-2 is involved in the development of colorectal cancer. We have previously shown that COX-2-derived prostacyclin participates in blastocyst implantation through activation of peroxisome proliferator activated receptor δ (PPARδ), a member of the nuclear hormone receptor family. Furthermore, our recent studies suggest that a similar pathway is operative during colorectal carcinogenesis. These observations prompted us to examine whether the COX-2-PPARδ signaling pathway is also involved during development of uterine adenocarcinoma. Here we describe for the first time the heightened expression of COX-2 and PPARδ, but not COX-1, in uterine endometrial adenocarcinoma.

Original languageEnglish (US)
Pages (from-to)483-490
Number of pages8
JournalNeoplasia
Volume2
Issue number6
StatePublished - 2000
Externally publishedYes

Fingerprint

Peroxisome Proliferator-Activated Receptors
Cyclooxygenase 2
Adenocarcinoma
Cyclooxygenase 1
Prostaglandins
Colorectal Neoplasms
Epoprostenol
Prostaglandin-Endoperoxide Synthases
Cytoplasmic and Nuclear Receptors
Epidemiologic Studies
Protein Isoforms
Carcinogenesis
Anti-Inflammatory Agents
Pharmacology
Mortality
Enzymes
Pharmaceutical Preparations

Keywords

  • Cyclooxygenase
  • Endometrial cancer
  • Human
  • Prostaglandins
  • Uterus

ASJC Scopus subject areas

  • Cancer Research

Cite this

Tong, B. J., Tan, J., Tajeda, L., Das, S. K., Chapman, J. A., DuBois, R. N., & Dey, S. K. (2000). Heightened expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-δ human endometrial adenocarcinoma. Neoplasia, 2(6), 483-490.

Heightened expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-δ human endometrial adenocarcinoma. / Tong, B. J.; Tan, J.; Tajeda, L.; Das, S. K.; Chapman, J. A.; DuBois, R. N.; Dey, S. K.

In: Neoplasia, Vol. 2, No. 6, 2000, p. 483-490.

Research output: Contribution to journalArticle

Tong, BJ, Tan, J, Tajeda, L, Das, SK, Chapman, JA, DuBois, RN & Dey, SK 2000, 'Heightened expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-δ human endometrial adenocarcinoma', Neoplasia, vol. 2, no. 6, pp. 483-490.
Tong, B. J. ; Tan, J. ; Tajeda, L. ; Das, S. K. ; Chapman, J. A. ; DuBois, R. N. ; Dey, S. K. / Heightened expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-δ human endometrial adenocarcinoma. In: Neoplasia. 2000 ; Vol. 2, No. 6. pp. 483-490.
@article{0513943ebc604b92bc8e235c4f151f3e,
title = "Heightened expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-δ human endometrial adenocarcinoma",
abstract = "Epidemiological studies indicate that nonsteroidal anti-inflammatory drugs (NSAIDs) significantly reduce the risk and mortality from colorectal cancer, in part by inhibiting prostaglandin (PG) synthesis. Cyclooxygenase (COX), the rate-limiting enzyme in PG biosynthesis, exists in two isoforms, COX-1 and COX-2. Genetic and pharmacological evidences suggest that COX-2 is involved in the development of colorectal cancer. We have previously shown that COX-2-derived prostacyclin participates in blastocyst implantation through activation of peroxisome proliferator activated receptor δ (PPARδ), a member of the nuclear hormone receptor family. Furthermore, our recent studies suggest that a similar pathway is operative during colorectal carcinogenesis. These observations prompted us to examine whether the COX-2-PPARδ signaling pathway is also involved during development of uterine adenocarcinoma. Here we describe for the first time the heightened expression of COX-2 and PPARδ, but not COX-1, in uterine endometrial adenocarcinoma.",
keywords = "Cyclooxygenase, Endometrial cancer, Human, Prostaglandins, Uterus",
author = "Tong, {B. J.} and J. Tan and L. Tajeda and Das, {S. K.} and Chapman, {J. A.} and DuBois, {R. N.} and Dey, {S. K.}",
year = "2000",
language = "English (US)",
volume = "2",
pages = "483--490",
journal = "Neoplasia",
issn = "1522-8002",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Heightened expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-δ human endometrial adenocarcinoma

AU - Tong, B. J.

AU - Tan, J.

AU - Tajeda, L.

AU - Das, S. K.

AU - Chapman, J. A.

AU - DuBois, R. N.

AU - Dey, S. K.

PY - 2000

Y1 - 2000

N2 - Epidemiological studies indicate that nonsteroidal anti-inflammatory drugs (NSAIDs) significantly reduce the risk and mortality from colorectal cancer, in part by inhibiting prostaglandin (PG) synthesis. Cyclooxygenase (COX), the rate-limiting enzyme in PG biosynthesis, exists in two isoforms, COX-1 and COX-2. Genetic and pharmacological evidences suggest that COX-2 is involved in the development of colorectal cancer. We have previously shown that COX-2-derived prostacyclin participates in blastocyst implantation through activation of peroxisome proliferator activated receptor δ (PPARδ), a member of the nuclear hormone receptor family. Furthermore, our recent studies suggest that a similar pathway is operative during colorectal carcinogenesis. These observations prompted us to examine whether the COX-2-PPARδ signaling pathway is also involved during development of uterine adenocarcinoma. Here we describe for the first time the heightened expression of COX-2 and PPARδ, but not COX-1, in uterine endometrial adenocarcinoma.

AB - Epidemiological studies indicate that nonsteroidal anti-inflammatory drugs (NSAIDs) significantly reduce the risk and mortality from colorectal cancer, in part by inhibiting prostaglandin (PG) synthesis. Cyclooxygenase (COX), the rate-limiting enzyme in PG biosynthesis, exists in two isoforms, COX-1 and COX-2. Genetic and pharmacological evidences suggest that COX-2 is involved in the development of colorectal cancer. We have previously shown that COX-2-derived prostacyclin participates in blastocyst implantation through activation of peroxisome proliferator activated receptor δ (PPARδ), a member of the nuclear hormone receptor family. Furthermore, our recent studies suggest that a similar pathway is operative during colorectal carcinogenesis. These observations prompted us to examine whether the COX-2-PPARδ signaling pathway is also involved during development of uterine adenocarcinoma. Here we describe for the first time the heightened expression of COX-2 and PPARδ, but not COX-1, in uterine endometrial adenocarcinoma.

KW - Cyclooxygenase

KW - Endometrial cancer

KW - Human

KW - Prostaglandins

KW - Uterus

UR - http://www.scopus.com/inward/record.url?scp=0034485955&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034485955&partnerID=8YFLogxK

M3 - Article

VL - 2

SP - 483

EP - 490

JO - Neoplasia

JF - Neoplasia

SN - 1522-8002

IS - 6

ER -